Annual review of EGFR inhibitors in 2024

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Epidermal growth factor receptor (EGFR) inhibitors are vital for treating cancers with specific EGFR mutations, including non-small cell lung cancer (NSCLC).
• The field saw significant advancements in 2024 concerning novel drug discovery, understanding resistance pathways, and developing combination therapy approaches.

Purpose of the Study:

• To review key research on EGFR inhibitors published in 2024.
• To focus on design strategies, structure-activity relationships (SAR), mechanisms of action, and preclinical (in vitro and in vivo) activities.
• To offer new perspectives for developing more effective and selective EGFR inhibitors against diverse mutations.

Main Methods:

• Literature review of studies published in 2024 focusing on EGFR inhibitors.
• Analysis of drug design, SAR, mechanisms of action, and experimental data (in vitro and in vivo).
• Synthesis of findings to identify trends and future research directions.

Main Results:

• Identification of novel EGFR inhibitor candidates with improved efficacy and selectivity.
• Elucidation of emerging resistance mechanisms and potential strategies to overcome them.
• Evaluation of promising combination therapy regimens involving EGFR inhibitors.

Conclusions:

• The 2024 research landscape offers promising avenues for next-generation EGFR inhibitors.
• Understanding SAR and resistance is key to overcoming treatment challenges in EGFR-driven cancers.
• Further development is needed to translate these findings into clinical practice for diverse EGFR mutations.